Spots Global Cancer Trial Database for Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia
Official Title: An Open Label Randomized Controlled Dose Escalating Phase II Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia
Study ID: NCT00512083
Conditions
Interventions
Study Description
Brief Summary: The overall aim of this study is to assess the efficacy and safety of AS1411, over a range of doses, when combined with cytarabine, in the treatment of patients with primary refractory or relapsed acute myeloid leukemia (AML).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UCLA Medical Center, Los Angeles, California, United States
Univeristy of Colorado Health Cancer Center, Aurora, Colorado, United States
St. Francis Hospital and Health Center, Beech Grove, Indiana, United States
University of Louisville, James Graham Brown Cancer Center, Louisville, Kentucky, United States
Washington University, St Louis, Missouri, United States
University of Nebraska Medical Center, Omaha, Nebraska, United States
Duke University Medical Center, Durham, North Carolina, United States
Medical University of South Carolina, Charleston, South Carolina, United States
Cancer Therapy and Research Center - Institute for Drug development, San Antonio, Texas, United States
Christchurch Hospital, Christchurch, , New Zealand
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
